What type of von Willebrand disease (vWD) is characterized by positive results for factor 8 activity, von Willebrand factor (vWF) antigen (vWF AG), and von Willebrand factor (vWF) activity?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Laboratory Pattern Interpretation: Type 1 von Willebrand Disease

When all three tests—factor VIII activity, VWF antigen (VWF:Ag), and VWF activity (VWF:RCo)—are positive (present but proportionately reduced together), this pattern is characteristic of Type 1 von Willebrand disease. 1

Diagnostic Laboratory Pattern

Type 1 VWD demonstrates a quantitative deficiency where all VWF parameters decrease proportionately: 1, 2

  • VWF:Ag: Reduced (typically 30-50% of normal)
  • VWF:RCo (activity): Reduced proportionately to VWF:Ag
  • Factor VIII activity: Reduced proportionately (since VWF carries FVIII in plasma)
  • VWF:RCo/VWF:Ag ratio: Normal (>0.5-0.7), distinguishing it from Type 2 variants 1

Key Distinguishing Features from Other VWD Types

Type 1 differs from Type 2 variants by maintaining a normal ratio between VWF activity and antigen: 1, 3

  • Type 2 VWD shows disproportionately low VWF:RCo compared to VWF:Ag (ratio <0.5-0.7), indicating qualitative dysfunction 1
  • Type 2 variants have abnormal VWF multimer patterns, while Type 1 shows all multimers present (just reduced in quantity) 3, 4

Type 1 differs from Type 3 by having detectable (though reduced) VWF levels: 3

  • Type 3 VWD shows absent or nearly absent (<3%) VWF:Ag, VWF:RCo, and very low FVIII 3

Critical Diagnostic Pitfalls to Avoid

VWF is an acute phase reactant, so levels can be falsely elevated during: 5, 6

  • Stress, inflammation, or recent surgery
  • Pregnancy or estrogen use
  • This can mask underlying Type 1 VWD, requiring repeat testing when the patient is at baseline 5, 6

High test variability (coefficient of variation 10-30% for VWF:RCo) means: 5, 6

  • Borderline results require repeat testing up to 3 times 5
  • Single normal results do not exclude VWD if clinical bleeding history is strong 5

Sample handling is critical: 1, 6

  • Process samples at room temperature to prevent cryoprecipitation of VWF 1
  • Improper collection can yield falsely abnormal results 6

When to Consider Type 1 Subtypes

Some Type 1 VWD patients have specific mechanisms requiring specialized testing: 7, 3

  • Type 1C (Vicenza): Rapid VWF clearance with unusually large multimers present; identified by elevated VWFpp/VWF:Ag ratio >10 7, 3
  • Type 1/2E: Multimerization defect with clearance issues; VWFpp/VWF:Ag ratio 3.2-4.7 3
  • These subtypes may respond differently to DDAVP (good initial response but rapid clearance) 3, 8

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Type 2B von Willebrand Disease Evaluation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Type 2B von Willebrand Disease Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2007

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.